Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) Non Operating Investment Income (2020 - 2023)

Avidity Biosciences (RNA) has disclosed Non Operating Investment Income for 4 consecutive years, with -$1.1 million as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Non Operating Investment Income fell 18.44% year-over-year to -$1.1 million, compared with a TTM value of $320000.0 through Jun 2023, up 110.72%, and an annual FY2022 reading of -$2.5 million, down 1279.67% over the prior year.
  • Non Operating Investment Income was -$1.1 million for Q2 2023 at Avidity Biosciences, down from $1.2 million in the prior quarter.
  • Across five years, Non Operating Investment Income topped out at $1.2 million in Q1 2023 and bottomed at -$1.8 million in Q1 2022.
  • Average Non Operating Investment Income over 4 years is -$242363.6, with a median of -$5000.0 recorded in 2020.
  • Peak annual rise in Non Operating Investment Income hit 511.29% in 2022, while the deepest fall reached 92050.0% in 2022.
  • Year by year, Non Operating Investment Income stood at -$5000.0 in 2020, then plummeted by 3620.0% to -$186000.0 in 2021, then soared by 511.29% to $765000.0 in 2022, then tumbled by 248.63% to -$1.1 million in 2023.
  • Business Quant data shows Non Operating Investment Income for RNA at -$1.1 million in Q2 2023, $1.2 million in Q1 2023, and $765000.0 in Q4 2022.